- Home
- ACIC vs ERAS Comparison
ACIC vs ERAS Comparison
Compare ACIC & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACIC | ERAS |
|---|---|---|
| Founded | 1999 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 625.2M | 1.0B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | ACIC | ERAS |
|---|---|---|
| Price | $12.70 | $3.42 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $3.71 |
| AVG Volume (30 Days) | 116.0K | ★ 2.6M |
| Earning Date | 11-05-2025 | 11-12-2025 |
| Dividend Yield | ★ 5.91% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.71 | N/A |
| Revenue | ★ $328,331,000.00 | N/A |
| Revenue This Year | $5.03 | N/A |
| Revenue Next Year | $2.40 | N/A |
| P/E Ratio | $7.32 | ★ N/A |
| Revenue Growth | ★ 22.22 | N/A |
| 52 Week Low | $9.97 | $1.01 |
| 52 Week High | $13.78 | $3.80 |
Technical Indicators
Market Signals| Indicator | ACIC | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 57.88 | 57.15 |
| Support Level | $12.51 | $3.32 |
| Resistance Level | $13.06 | $3.77 |
| Average True Range (ATR) | 0.26 | 0.25 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 67.25 | 45.19 |
Price Performance
Historical ComparisonAbout ACIC American Coastal Insurance Corporation
American Coastal Insurance Corp is a holding company that underwrites commercial residential property and casualty insurance policies in the United States through its wholly-owned insurance subsidiary.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.